Key Highlights

  • ResMed announced a definitive agreement to transfer MatrixCare to Frazier Healthcare Partners for $490 million in cash.
  • The MatrixCare segment generated roughly $220 million in revenue and about $55 million in non‑GAAP operating profit for fiscal 2026.
  • The recent acquisition of Noctrix is projected to add $30 million of revenue while trimming non‑GAAP diluted EPS by $0.20 in fiscal 2027.

ResMed (NYSE: RMD) disclosed a strategic divestiture of its MatrixCare business. The transaction, valued at $490 million, was finalized on June 30, 2026, and is slated to close in the first quarter of fiscal 2027, pending customary approvals. Net proceeds will be directed toward an accelerated share repurchase (ASR) and general corporate purposes.

Transaction Overview

The all‑cash deal with private‑equity firm Frazier Healthcare Partners will transfer ownership of MatrixCare, a health‑technology platform that contributed approximately $220 million in revenue and $55 million in non‑GAAP operating profit for fiscal 2026. Both parties anticipate transition service agreements to preserve operational continuity and mitigate early post‑closing costs.

Capital Allocation Plan

ResMed plans to allocate the cash received to fund an accelerated share repurchase program, a move aimed at returning capital directly to shareholders. The company also noted that residual costs associated with the transition will be managed over time, aligning with its broader financial strategy.

Impact of Recent Acquisitions

The acquisition of Noctrix, completed earlier in the year, is expected to generate about $30 million of additional revenue. However, the integration will reduce non‑GAAP diluted earnings per share by roughly $0.20 in fiscal 2027, reflecting the incremental expense profile of the new assets.

Outlook for Remaining Segments

ResMed reaffirmed its expectation that the Residential Care Software segment will continue to grow at a high single‑digit percentage rate year over year. The company also anticipates operating leverage improvements within this segment for fiscal 2027, although detailed guidance will be shared during its upcoming earnings call on August 6, 2026.

Guidance and Investor Communication

During its fiscal 2026 third‑quarter earnings call on April 30, 2026, ResMed reiterated guidance for non‑GAAP gross margin, SG&A, R&D spend as a share of revenue, and tax rate. The firm emphasized its commitment to returning capital to shareholders through the planned share repurchase initiative, while remaining focused on execution of its long‑term strategic priorities. Full fiscal 2027 expectations will be disclosed later in August.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.